At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b Study of Talimogene Laherparepvec in Combination With Atezolizumab in Subjects With Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases
In Brief
A Phase 1 clinical trial evaluating Talimogene Laherparepvec and Atezolizumab for Metastatic Triple Negative Breast Cancer and Metastatic Colorectal Cancer. Completed, enrolled 36 participants across 17 sites in 6 countries.
Detailed Summary
Approximately 36 DLT-evaluable subjects will be enrolled in this study. The locations of the study will be in the United States, Australia, Europe and Switzerland. The goal of this study is to evaluate the safety of intrahepatic injection (directly into the liver) of talimogene laherparepvec in combination with intravenously administered atezolizumab in subjects with triple negative breast cancer and colorectal cancer with liver metastases.
Study Details
Timeline
Interventions
Virally based anti-cancer immunotherapy given by direct injection into tumors.
A monoclonal antibody given by intravenous injection.